A major pro-life organization has filed a formal notice of intent to sue the Food and Drug Administration under the Trump administration, alleging the agency never conducted a legally required environmental review before approving the abortion drug mifepristone. The move puts a Republican-led FDA in an unusual position: facing legal fire from a core conservative constituency over a pill that remains one of the most contested products in American medicine.
Americans United for Life, one of the oldest anti-abortion legal groups in the country, sent the notice to the FDA on Monday, as Fox News first reported. The letter argues that the agency violated the National Environmental Policy Act, known as NEPA, a federal law requiring agencies to assess environmental consequences before taking major regulatory actions. AUL contends the FDA skipped that step entirely when it approved mifepristone and has never gone back to fix the omission.
The claim rests on a straightforward premise. NEPA requires federal agencies to prepare an environmental impact statement or at least an environmental assessment before approving actions that could affect the natural environment. AUL argues that mifepristone, which is used in medication abortions and results in the passage of fetal tissue and blood, enters the water supply and broader environment through sewage systems. The group claims the FDA has never studied what happens when those biological materials and drug metabolites reach waterways, soil, or wildlife.
AUL President and CEO Steven Aden framed the issue in blunt terms. He said the FDA has "completely ignored" its obligations under NEPA and that the agency's failure to act amounts to a regulatory blind spot with real consequences for public health and the environment.
"The FDA has never once conducted the environmental review that federal law demands before approving a drug that ends up in our water and our ecosystems."
The organization's legal team argues this is not a novel theory. NEPA applies broadly to federal agency actions, and courts have enforced it against agencies that skip environmental review in other regulatory contexts. AUL says the FDA has no valid exemption from the statute for drug approvals of this kind.
The timing and target raise an obvious question. Pro-life groups have spent years battling the FDA over mifepristone access, but those fights took place under Democratic administrations or through the courts. Now, with a Republican president in the White House and an FDA commissioner presumably more sympathetic to conservative concerns, AUL is choosing confrontation over quiet lobbying.
The notice of intent to sue is a procedural prerequisite under NEPA. It gives the agency a defined window, typically 60 days, to respond or take corrective action before AUL can file suit in federal court. If the FDA does not act, AUL has signaled it will move forward with litigation.
The group made clear it views the current administration's inaction on the pill as a failure. AUL's notice specifically calls on the Trump FDA to initiate a full environmental impact review of mifepristone's approval and its continued availability. The organization argues that every day the drug remains on the market without that review, the agency is in ongoing violation of federal law.
Mifepristone was first approved by the FDA in 2000 under the Clinton administration. The drug blocks progesterone, a hormone necessary to sustain a pregnancy, and is used in combination with a second drug, misoprostol, to complete a medication abortion. The FDA approved it under a special restricted distribution program known as a Risk Evaluation and Mitigation Strategy, or REMS, which imposed limits on how and where the drug could be dispensed.
Over the past two decades, the FDA loosened several of those restrictions. Under the Biden administration, the agency eliminated the in-person dispensing requirement and allowed mifepristone to be prescribed via telehealth and shipped by mail. Those changes dramatically expanded access and made medication abortion the most common method of ending a pregnancy in the United States.
Pro-life groups challenged the FDA's regulatory decisions in court. The most prominent case, Alliance for Hippocratic Medicine v. FDA, reached the Supreme Court in 2024. The justices unanimously dismissed that challenge on standing grounds, ruling that the plaintiffs had not shown a concrete injury. The decision did not address the merits of the FDA's approval or its subsequent regulatory changes.
AUL's new approach sidesteps the standing problem that sank the previous case. Environmental claims under NEPA carry their own standing framework, and the group argues that the environmental harm from mifepristone's unreviewed approval is concrete, traceable, and redressable by a court order requiring the FDA to conduct the review.
AUL's notice lays out several specific environmental concerns. The group claims that mifepristone and its metabolites pass through wastewater treatment systems without being fully removed. Once in waterways, the organization argues, these substances could affect aquatic life, particularly species sensitive to hormonal disruption.
The group also raises concerns about the biological tissue expelled during medication abortions. AUL argues that fetal remains and associated blood entering sewage systems present a distinct category of environmental impact that the FDA has never evaluated. The notice contends that the sheer volume of medication abortions, now exceeding one million per year in the United States by some estimates, magnifies whatever environmental effect exists.
AUL acknowledged that no comprehensive study of mifepristone's environmental footprint currently exists. But the group argues that is precisely the point. NEPA does not require a plaintiff to prove environmental harm before suing. It requires the agency to look before it leaps. The statute's purpose is to force the government to study potential impacts before they occur, not after.
The FDA has not publicly responded to AUL's notice. The agency has historically taken the position that individual drug approvals do not trigger NEPA review, relying on categorical exclusions that exempt certain regulatory actions from environmental assessment requirements.
Legal experts following the case say the FDA will almost certainly argue that its drug approval process falls within one of NEPA's categorical exclusions. The agency may also argue that AUL lacks standing or that the environmental claims are too speculative to support judicial intervention.
But AUL appears to have anticipated those defenses. The group's notice argues that no categorical exclusion applies to a drug with the volume, biological characteristics, and environmental profile of mifepristone. The organization also cites the FDA's own regulations, which require agencies to prepare an environmental assessment when a proposed action may have a significant effect on the human environment, even if a categorical exclusion might otherwise apply.
The lawsuit threat also reflects growing frustration among pro-life organizations with the pace of action under the current administration. Several groups have publicly pressed the Trump White House and FDA to take administrative steps to restrict mifepristone, including reimposing the in-person dispensing requirement, tightening REMS protocols, or withdrawing the drug's approval altogether.
So far, the administration has not taken any of those steps. The FDA under Trump's appointed leadership has left the Biden-era regulatory framework for mifepristone largely intact. That inaction has cause tension between the White House and its pro-life base, with some activists accusing the administration of deprioritizing the issue.
AUL's decision to file a formal legal threat rather than rely on behind-the-scenes advocacy signals that at least some pro-life leaders have concluded that waiting for executive action is not a viable strategy. The notice puts the administration on a public clock.
If the FDA does not initiate an environmental review within the notice period, AUL can file suit in federal court. The case would likely be filed in a jurisdiction favorable to the organization's claims, following the pattern of recent conservative legal challenges to federal agency action.
A successful suit could force the FDA to halt or restrict mifepristone distribution while it conducts the required environmental review, a process that can take months or years depending on scope. That outcome would represent a significant disruption to medication abortion access, achieving through environmental law what the Supreme Court's standing ruling blocked through direct regulatory challenge.
Investigators and regulators will need to determine whether mifepristone and its byproducts pose any measurable environmental risk, a question no federal agency has formally studied. The FDA has not publicly indicated whether it views AUL's NEPA theory as legally viable or whether it plans to take any action in response to the notice.
For now, the ball sits with the Trump FDA. A pro-life movement that helped put this administration in power is telling its own allies that good intentions are not enough and that the law demands more than inaction dressed up as deliberation.
